The last filed quarter gives the baseline. In the second quarter of 2026 revenue was USD 149.7 million, up 52%, net transactionMarginwas 63.5%,Marketingspend was USD 19.4 million, purchase frequency reached a record 7.2 times and about 140,000 net new subscribers joined. Gross merchandise volume …
The headline revenue growth of 5.1% hides a sharp change in product mix. ASCENIV, the company's immunoglobulin for primary humoral immunodeficiency, generated USD 124.7 million, up 30.7% year over year and up 21% from the second quarter. BIVIGAM revenue fell 35.2% to USD 15.4 …
For the fiscal year ended March 31, 2026, the audited net loss was USD 5.0 million, down from USD 6.1 million, withResearch and Developmentat USD 3.7 million, up from USD 2.0 million, and general and administrative expenses at USD 2.7 million, down from USD …
The pipeline is centred on EVO756, an oral drug for immune-driven skin and neurological conditions. In June 2026 its Phase 2b chronic spontaneous urticaria study missed its primary endpoint at all doses, and the company discontinued development in that condition. A Phase 2b atopic …
Nine-month figures show the strain behind the improvement. Revenue was USD 11.1 million versus USD 12.6 million, and the net loss was USD 6.8 million, or USD 0.31 per share, versus USD 4.4 million, or USD 0.21. The company said cost-reduction actions taken earlier …
Key HighlightsAppLovin (NASDAQ:APP) was quoted 16.67% higher at USD 317.04 in premarket trading on November 5, 2026, following its third-quarter 2026 report for the period ended September 30, 2026.Third-quarterRevenuewas USD 2.18 billion, up about 55% from USD 1.41 billion a year earlier, withNet Incomeof …
Management framed the quarter as an inflection. Chief Executive Mary Powell said the company has returned its direct business to growth, with installations up 9% year over year, and Chief Financial Officer Danny Abajian called the quarter an important inflection point. Subscribers totaled 1,057,695 …
A standby equity purchase agreement lets a company sell new shares to an investor at a discount to market over time, which supplies cash but dilutes existing holders, so a rising cash balance often comes with a rising share count. The release did not …
The reportedBottom Linelooks weak: the company recorded a net loss of USD 46.6 million, against net income of USD 4.0 million in the prior-year quarter. Adjusted EBITDA strips out items such as stock-based pay and other non-cash or one-time charges, so it can diverge …
Nasdaq gives a company 180 calendar days to cure a bid price deficiency, which for WiMi runs to April 28, 2027. Compliance returns once the closing bid is at least USD 1.00 for a minimum of 10 consecutive business days. If not, a second …